Publications Gjertsen

2025

    1. Trung Quang Ha, Vibeke Andresen , Bjarte Skoe Erikstein, Mihaela Popa, Stein-Erik Gullaksen, Håkon Reikvam, Emmet McCormack, Bjørn Tore Gjertsen. Preclinical activity of resazurin in acute myeloid leukaemia. Br J Haematol. 2025 Jan;206(1):109-119. doi: 10.1111/bjh.19872
    2.  Venanzi A, Cardinali V, Perriello V, Albano F, Cimino G, Martino G, Marra A, Sportoletti P, Andresen V, Gjertsen BT, Sica S, Chiusolo P, Martelli MP, Tiacci E, Falini B. Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2025 Jan;100(1):139-143. doi: 10.1002/ajh.27415. Epub 2024 Jun 22. PMID: 39158266.

2024

    1. Sefland Ø, Gullaksen SE, Omsland M, Reikvam H, Galteland E, Tran HTT, Spetalen S, Singh SK, Van Zeeburg HJT, Van De Loosdrecht AA, Gjertsen BT. Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. Cytometry B Clin Cytom. 2024 Jul 30. doi: 10.1002/cyto.b.22197
    2. Mathisen AF, Larsen U, Kavli N, Unger L, Vacaru AM, Daian LM, Vacaru A-M, Herrera PL, Ghila L, Chera S. Moderate beta-cell ablation triggers synergic compensatory mechanisms even in the absence of overt metabolic disruption. Commun Biol 7, 833 (2024). https://doi.org/10.1038/s42003-024-06527-5
    3. Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med. 2024 Jun 18;5(6):101572. doi: 10.1016/j.xcrm.2024.101572. Epub 2024 May 15. PMID: 38754420; PMCID: PMC11228397.
    4. Eldfors S, Saad J, Ikonen N, Malani D, Vähä-Koskela M, Gjertsen BT, Kontro M, Porkka K, Heckman CA. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood Adv. 2024 Apr 9;8(7):1621-1633. doi: 10.1182/bloodadvances.2023010435. PMID: 38197948; PMCID: PMC10987804.
    5. Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson- Strömberg U. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. Epub 2024 Jan 26. Erratum in: Leukemia. 2024 Apr;38(4):925. doi: 10.1038/s41375-024-02184-z. PMID: 38278960; PMCID: PMC10997502.
    6.  Hemminki K, Zitricky F, Försti A, Kontro M, Gjertsen BT, Severinsen MT, Juliusson G. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Blood Cancer J. 2024 Mar 14;14(1):44. doi: 10.1038/s41408-024-01033-7. PMID: 38480693; PMCID: PMC10937905
    7. Khan AA, James D, Andresen V, Atkey J, Bradbury R, Cargo C, Dillon R, Gjertsen BT, Goldstone AR, Leach R, Lock D, Narayanan M, Russell N, Verigou EA, Green S, Fielding AK, Falini B. Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations. Am J Hematol. 2024 Oct;99(10):2018-2022. doi: 10.1002/ajh.27301. Epub 2024 Apr 3. PMID: 38567798.
    8. Kleftogiannis D, Gavasso S, Tislevoll BS, van der Meer N, Motzfeldt IKF, Hellesøy M, Gullaksen SE, Griessinger E, Fagerholt O, Lenartova A, Fløisand Y, Schuringa JJ, Gjertsen BT, Jonassen I. Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry. iScience. 2024 Jun 12;27(7):110261. doi: 10.1016/j.isci.2024.110261. PMID: 39021803; PMCID: PMC11253510.
    9. Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Leukemia. 2024 Apr;38(4):925. doi: 10.1038/s41375-024-02184-z. Erratum for: Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. PMID: 38418611; PMCID: PMC10997495.
    10. Sefland Ø, Gullaksen SE, Omsland M, Reikvam H, Galteland E, Tran HTT, Spetalen S, Singh SK, Van Zeeburg HJT, Van De Loosdrecht AA, Gjertsen BT. Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease. Cytometry B Clin Cytom. 2024 Nov;106(6):485-496. doi: 10.1002/cyto.b.22197. Epub 2024 Jul 30. PMID: 39078053.

2023

    1. Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Early response evaluation by single cell signaling profiling in acute myeloid leukemia.  Nat Commun. 2023 Jan 7;14(1):115. doi: 10.1038/s41467-022-35624-4